{"id":"experimental-vehicle-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Transient vision blurring"}]},"_chembl":{"chemblId":"CHEMBL2108661","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vehicle ophthalmic solutions serve as inert or minimally active carrier formulations that optimize drug delivery to ocular tissues. They typically contain buffering agents, osmolarity adjusters, and preservatives to maintain corneal integrity and enhance penetration of active pharmaceutical ingredients. The specific mechanism depends on the active agent being delivered, which is not specified for this experimental formulation.","oneSentence":"A vehicle ophthalmic solution formulation designed to deliver therapeutic agents to the eye while maintaining ocular surface stability and drug bioavailability.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:00.415Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:39:17.065294+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Ophthalmic indication (specific indication not disclosed for this vehicle formulation)"}]},"trialDetails":[{"nctId":"NCT06538662","phase":"PHASE3","title":"An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-10-07","conditions":"Ocular Redness, Eye Irritation","enrollment":283},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT06444529","phase":"PHASE3","title":"A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-08-21","conditions":"Ocular Redness","enrollment":159},{"nctId":"NCT06209320","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-03-15","conditions":"Myopia","enrollment":777},{"nctId":"NCT05591755","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-11-18","conditions":"Seasonal Allergic Conjunctivitis","enrollment":229},{"nctId":"NCT06249152","phase":"PHASE2","title":"Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2024-04-21","conditions":"Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma","enrollment":36},{"nctId":"NCT06016972","phase":"PHASE2","title":"Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2024-03-05","conditions":"Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye","enrollment":63},{"nctId":"NCT04909450","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects","status":"COMPLETED","sponsor":"Claris Biotherapeutics, Inc.","startDate":"2021-08-24","conditions":"Neurotrophic Keratitis","enrollment":131},{"nctId":"NCT04770610","phase":"PHASE3","title":"Study of OT-101 in Treating Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocumension (Hong Kong) Limited","startDate":"2021-04-01","conditions":"Myopia, Progressive","enrollment":678},{"nctId":"NCT05677945","phase":"NA","title":"3Mixtatin Versus Modified 3Mix-MP in Lesion Sterilization and Tissue Repair for Treatment of Necrotic Primary Molars","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-03","conditions":"Necrotic Primary Molars","enrollment":24},{"nctId":"NCT03889886","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Silk Technologies, Ltd.","startDate":"2019-04-16","conditions":"Dry Eye","enrollment":305},{"nctId":"NCT04535947","phase":"PHASE2","title":"Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)","status":"COMPLETED","sponsor":"Silk Technologies, Ltd.","startDate":"2020-08-14","conditions":"Dry Eye","enrollment":153},{"nctId":"NCT04541888","phase":"PHASE3","title":"Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2020-11-05","conditions":"Dry Eye","enrollment":644},{"nctId":"NCT02373397","phase":"NA","title":"Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy","status":"TERMINATED","sponsor":"Neil Lagali","startDate":"2015-03","conditions":"Corneal Dystrophy, Epithelial Basement Membrane, Epithelial Recurrent Erosion Dystrophy, Corneal Erosions","enrollment":40},{"nctId":"NCT03230058","phase":"PHASE2, PHASE3","title":"Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis","status":"UNKNOWN","sponsor":"L.V. Prasad Eye Institute","startDate":"2017-01-01","conditions":"Infection, Fungal","enrollment":55},{"nctId":"NCT01998802","phase":"PHASE3","title":"Phase 3 Study of EBI-005 in Dry Eye Disease","status":"COMPLETED","sponsor":"Eleven Biotherapeutics","startDate":"2014-01","conditions":"Dry Eye Disease (DED)","enrollment":670},{"nctId":"NCT02405039","phase":"PHASE3","title":"Study of EBI-005 in Dry Eye Disease (DED)","status":"UNKNOWN","sponsor":"Eleven Biotherapeutics","startDate":"2015-04","conditions":"Dry Eye","enrollment":188},{"nctId":"NCT01698814","phase":"PHASE3","title":"A Six-Week Safety Study of an Investigational Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-10","conditions":"Allergic Conjunctivitis","enrollment":518},{"nctId":"NCT00833495","phase":"PHASE2","title":"Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation","status":"COMPLETED","sponsor":"Fovea Pharmaceuticals SA","startDate":"2009-01","conditions":"Allergic Conjunctivitis","enrollment":155},{"nctId":"NCT00069706","phase":"PHASE2","title":"Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-07","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":118},{"nctId":"NCT00293800","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT00293787","phase":"PHASE3","title":"A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental: Vehicle ophthalmic solution","genericName":"Experimental: Vehicle ophthalmic solution","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A vehicle ophthalmic solution formulation designed to deliver therapeutic agents to the eye while maintaining ocular surface stability and drug bioavailability. Used for Ophthalmic indication (specific indication not disclosed for this vehicle formulation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":10,"withResults":3},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:39:17.065294+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}